biostudies-literatureLazarus RNational Institute for Health Research (NIHR)2277-2287https://www.ebi.ac.uk/biostudies/studies/S-EPMC8585490biostudies-literatureUnknown398(10318)<h4>Background</h4>Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.<h4>Methods</h4>In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine. 3 weeks later the group who received placebo received the influenza vaccine, and vice versa. Participants were followed up for 6 weeks. The influenza vaccines were three seasonal, inactivated vaccines (trivalent, MLancet (London, England)Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.PMC8585490NIHR203243Haynes MNguyen-Van-Tam JSOliver COliver EBradburn KFeltham SLeach RWilliams JRampling TBurge SWilliams GHarrhy SJoyce KAlaee SRicamara MTalbot HManning NColeman THalliday APaterson JGardiner SOwen DMoran EBroad LHutton DTownley GClose AFinn ADavies RMcLaughlin MHazell MDavies LFarrow AFrayling SDavies KSilva LCarmichael DRyan JPearce LClark TDavies CRice DHewson JBray JJHDriver KLloyd ANyland KPegler SFaulkner BStringer RThomas ABowles JDavid Otter ATurkentine KCowley CHaxton LNicholls LAwal TBird SEkblad CSmith RMPrice ZTurner KCappel-Porter HBressington CD'Agostino AAllum EPynsent WBThirard RCross ETyler JHallis BShankland SBarnett LTaylor SLKellett Wright JHamal SAdams KYoulden NTodd RGarstang JAnthony SBeard CWilliams RLSeneviratne MBishop SRamos LYim YTNKirby ACarson-Stevens AHiggins TRegan KHicks BWarnes BPrice EFord JRogers CALangton HMills BEglinton CAshton KBrydon-Hill RMcCullagh LBarratt ABodalia PComfluCOV Trial GroupEvans MSakagami YLazarus RHill MGoodwin JWalton MKaminski RBisset JEvans TFigueirido STrembath LRea DUgoji JMcFadzean IJSmart KEvans IIqbal AMiddleditch ALamb JHitchings BJones NWale KLibri VBaum HSeaman SJones LKnibbs LGooch KETilzey GNaik GWhittley SSantoloce SHills AIftikhar HKidd SPhillipson ATucker DF Mujadidi YHembrough TCranfield CNorman CRich MSalem AClout MSnape MDEmmett SRBowyer CBrimfield MWalker-Smith THua CBaos SMcQueen AWilliamson KRyan KASalter-Hewitt JJacobsen NRoots MRiaz THilton ZCulliford LMarriott ABarron CBennett LNorthcott KSmith JD'Arcangelo SHarris RABrown PSamuels MGbadamoshi LHarris AFoxwell DEldridge ELewis-Clarke PMaclean KOliver JChohan GAley PKTarling TfalseSafety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.<h4>Background</h4>Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.<h4>Methods</h4>In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine. 3 weeks later the group who received placebo received the influenza vaccine, and vice versa. Participants were followed up for 6 weeks. The influenza vaccines were three seasonal, inactivated vaccines (trivalent, M2021-01-01T00:00:00Z2021 Dec2026-05-08T08:49:55.606Z2022-02-11T14:57:18.581ZS-EPMC85854903477419710.1016/S0140-6736(21)02329-1